The alternative would for someone to bid to buy Rock Creek and the IP seeking to wipe out the existing shareholders and then bring the company back with a new name and funding to develop the drug. This approach might make sense to some buyer taking into consideration the NOL carry forward.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.